Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesGuidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting
Bulletin du Cancer, 10/19/09
Durand J–P et al. – It is essential to distinguish between the anticipatory, acute (first 24 hours) and delayed phases of CINV, to take into account the emetogenic potential of the different chemotherapy protocols (very low, low, moderate and high) together with individual risk factors. The authors would like to propose methodological and therapeutic recommendations for the primary and secondary prophylaxis of the acute and delayed phases of CINV.
Related Articles
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
Cancer, 10/20/09
Relevance Score: 67%
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/10/09
Relevance Score: 43%
Supplemental oxygen and the incidence of perioperative nausea and vomiting in cesarean sections under subarachnoid block
Revista Brasileira de Anestesiologia, 10/05/09
Relevance Score: 43%
Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study
Annals of Oncology, 10/16/09
Relevance Score: 42%
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Journal of Clinical Oncology, 10/08/09
Relevance Score: 42%
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Journal of the National Cancer Institute, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor